Agenda

 

 

Thursday, January 24 2019

09:00 am - 09:15 am
Welcome and opening remarks
09:15 am - 10:00 am
Key Note address by Dr. Craig Thomas

National Center for Advancing Translational Sciences (NCATS/NIH)

Accelerating Translation:

  •  Strategies for Rapid Probe Development
  • Drug Combination Discovery and Precision Medicine. 

Novel combinations

10:00 am - 10:20 am
Brittany Bivens, NMRC

Developing Bacteriophage Cocktails to Target Resistant Isolates That Emerge During Treatment

10:20 am - 10:40 am
Dr. Rekha Panchal, USAMRIID

Small molecule adjuvants in combination with antibiotics to overcome infections caused by multi-drug resistant bacteria

10:40 am - 11:00 am

Break

Novel technologies

11:00 am - 11:20 am
Dr. Stuart Le Grice, NCI

Small Molecule Targeting of Cellular and Viral RNAs

11:20 am - 11:40 am
Dr. Francisco Malagon, NMRC

Phage-Mediated Molecular Detection of Staphylococcus aureus

11:40 am - 12:00 pm
Matthew Henry, NMRC

Personalized Phage Therapy of a Lung Transplant Patient Infected with Antibiotic-Resistant Pseudomonas aeruginosa

 

12:00 pm - 01:00 pm

Lunch

01:00 pm - 01:20 pm
Dr. Ji Hyun Lee, IRF/NIAID

Evaluation of Post-exposure ZMappTM Infusion against Challenge with Aerosolized Ebola Virus

 

Novel targets or chemical classes

01:20 pm - 01:40 pm
Dr. Amy Funk, NCI

Leucine zipper-bearing kinase (LZK) is a novel therapeutic target in head and neck squamous cell carcinoma patients with 3q amplification

01:40 pm - 02:00 pm
Dr. Kamal Saikh, USAMRIID

A small molecule inhibitor of MyD88 exhibits broad spectrum antiviral activity by upregulation of Type I Interferon

02:00 pm - 02:20 pm

Break

02:20 pm - 02:40 pm
Dr. Pedro Torres-Ayuso, CCR/NCI

TNIK, a novel druggable dependency in lung squamous cell carcinoma 

02:40 pm - 03:00 pm
Dr. Julio Valencia, NCI

Blockade of the cross-regulation of IFNg and IL-27 limits immunotherapy-induced immune-related adverse events in a murine model of systemic lupus erythematosus

03:00 pm - 03:20 pm
Dr. Curtis Henrich, NCI

Discovery of natural product modulators of Merkel Cell Carcinoma (MCC) cell viability

03:20 pm - 03:40 pm

Concluding Remarks